Ptc Therape receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PTC Therapeutics Inc (PTCT)
PTC Therapeutics Inc stock price live, this page displays NASDAQ PTCT stock exchange data. View the PTCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PTC Therapeutics Inc real time stock price chart below.
What Is the PTC Therapeutics Inc Stock Price Today?
The PTC Therapeutics Inc stock price today is 68.01.
What Is the Stock Symbol for PTC Therapeutics Inc?
The stock symbol for PTC Therapeutics Inc is "PTCT."
What Stock Exchange Does PTC Therapeutics Inc Trade On?
PTC Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is PTC Therapeutics Inc a Good Stock to Buy?
Determining whether PTC Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTCT quote. (ISIN: US69366J2006)
What Is the PTC Therapeutics Inc Stock Price Today?
The PTC Therapeutics Inc stock price today is 68.01.
What Is the Stock Symbol for PTC Therapeutics Inc?
The stock symbol for PTC Therapeutics Inc is "PTCT."
What Stock Exchange Does PTC Therapeutics Inc Trade On?
PTC Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is PTC Therapeutics Inc a Good Stock to Buy?
Determining whether PTC Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTCT quote. (ISIN: US69366J2006)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.57
73.72
52 wk Range
43.18
90.87
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.5773.72
52 wk Range
43.1890.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PTCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
97.86
Upside
+43.89%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Ptc Therape receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 4 PTC Therapeutics Inc For: 30 July- Investing.com
- Ptc Therape receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ptc Therape receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 4 PTC Therapeutics Inc For: 30 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
11 Buy
2 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 97.86
(+43.89% Upside)
PTC Therapeutics Inc SWOT Analysis
Pipeline Promise | Explore PTC Therapeutics' diverse rare disease portfolio, with sepiapterin for PKU and vatiquinone for FA leading potential blockbuster candidates |
Financial Foundations | Delve into PTCT's robust $2 billion cash position and strong gross margins, providing stability amid pivotal regulatory decisions |
Market Momentum | Learn how PTCT's established presence in DMD and SMA markets positions it for growth, with analyst price targets ranging from $40 to $113 |
Strategic Challenges | Uncover the regulatory hurdles and competitive pressures facing PTCT as it aims to launch new treatments and maintain market leadership |
PTC Therapeutics Inc Earnings Call Summary for Q2/2026
- PTC Therapeutics Q2 2026 EPS of $0.92 beat estimates by 188%, with revenue of $361M topping forecasts by 23% on strong Sephience sales.
- Company raised full-year 2026 revenue guidance to $1.18B-$1.28B, expects potential cash flow breakeven, citing Sephience momentum.
- Sephience revenue hit $161M, up 21% sequentially; 1,647 patients on therapy globally with 100% of U.S. centers of excellence prescribing.
- Cash position strengthened to $2.23B at quarter-end, up $280M from year-end 2025, providing capacity for investments and acquisitions.
- Key catalysts ahead include Germany reimbursement decision H2 2026, PTC612 Phase I data late 2026/early 2027, and votoplam FDA discussions.
Last Updated: 2026/07/30, 23:48
Read Full TranscriptEarnings
Latest Release
Jul 30, 2026
EPS / Forecast
0,92 / 0,32
Revenue / Forecast
361M / 293,07M
Compare PTCT to Peers and Sector
Metrics to compare | PTCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −147.9x | −1.3x | −0.4x | |
PEG Ratio | 1.39 | −0.05 | 0.00 | |
Price/Book | −34.3x | 1.2x | 2.6x | |
Price / LTM Sales | 5.6x | 42.6x | 3.0x | |
Upside (Analyst Target) | 44.1% | 185.5% | 56.0% | |
Fair Value Upside | Unlock | 19.5% | 9.1% | Unlock |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the PTC Therapeutics (PTCT) Stock Price Today?
The PTC Therapeutics stock price today is 68,01 USD.
What Stock Exchange Does PTC Therapeutics Trade On?
PTC Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PTC Therapeutics?
The stock symbol for PTC Therapeutics is "PTCT."
What Is the PTC Therapeutics Market Cap?
As of today, PTC Therapeutics market cap is 5,68B USD.
What Is PTC Therapeutics's Earnings Per Share (TTM)?
The PTC Therapeutics EPS (TTM) is -0,47.
When Is the Next PTC Therapeutics Earnings Date?
PTC Therapeutics will release its next earnings report on Oct 22, 2026.
From a Technical Analysis Perspective, Is PTCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has PTC Therapeutics Stock Split?
PTC Therapeutics has split 0 times.
How Many Employees Does PTC Therapeutics Have?
PTC Therapeutics has 991 employees.
What is the current trading status of PTC Therapeutics (PTCT)?
As of Aug 03, 2026, PTC Therapeutics (PTCT) is trading at a price of 68,01 USD, with a previous close of 68,01 USD. The stock has fluctuated within a day range of 64,57 USD to 73,72 USD, while its 52-week range spans from 43,18 USD to 90,87 USD.
What Is PTC Therapeutics (PTCT) Price Target According to Analysts?
The average 12-month price target for PTC Therapeutics is 97,86 USD, with a high estimate of 130 USD and a low estimate of 70 USD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +43,89% Upside potential.
What Is the PTCT After Hours Price?
PTCT's last after hours stock price is 69,24 USD, the stock has decreased by 1,23, or 1,81%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.